BioAtla. has filed a patent for isolated polypeptides that specifically bind to CD46 protein. The patent also covers antibodies and antibody fragments containing these polypeptides, as well as immunoconjugates, pharmaceutical compositions, and kits. The polypeptides have a light chain variable region with three complementary determining regions (CDRs) with specific sequences. GlobalData’s report on BioAtla gives a 360-degree view of the company including its patenting strategy. Buy the report here.

Smarter leaders trust GlobalData

Report-cover

Data Insights BioAtla Inc - Company Profile

Buy the Report

Data Insights

The gold standard of business intelligence.

Find out more

According to GlobalData’s company profile on BioAtla, Personalized cancer vaccines was a key innovation area identified from patents. BioAtla's grant share as of September 2023 was 34%. Grant share is based on the ratio of number of grants to total number of patents.

Isolated polypeptides that bind to cd46 protein

Source: United States Patent and Trademark Office (USPTO). Credit: BioAtla Inc

A recently filed patent (Publication Number: US20230242662A1) describes isolated polypeptides and antibodies for the treatment of cancer. The patent claims include specific sequences of amino acids that make up the light chain variable region and heavy chain variable region of the polypeptides and antibodies. These sequences, known as complementary determining regions (CDRs), are important for the binding of the polypeptides and antibodies to the human CD46 protein.

The patent claims also describe the use of these polypeptides and antibodies in immunoconjugates, which are combinations of the antibodies or antibody fragments with other agents such as chemotherapeutic agents, radioactive atoms, cytostatic agents, or cytotoxic agents. The immunoconjugates can be used for targeted delivery of these agents to cancer cells.

Furthermore, the patent claims include pharmaceutical compositions comprising the polypeptides, antibodies, or immunoconjugates, along with a pharmaceutically acceptable carrier. These compositions can be used for the diagnosis or treatment of cancer.

The patent claims also cover methods of treating cancer by administering the polypeptides, antibodies, or immunoconjugates to patients with cancer. Additionally, the patent claims describe a kit for diagnosis or treatment, which includes the antibodies or antibody fragments along with instructions for their use.

Overall, this patent application presents a range of claims related to isolated polypeptides, antibodies, immunoconjugates, pharmaceutical compositions, and methods of treatment for cancer. These claims highlight the potential of these novel therapeutic agents for targeted cancer therapy and provide a basis for further research and development in the field.

To know more about GlobalData’s detailed insights on BioAtla, buy the report here.

Data Insights

From

The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.

GlobalData

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies